Hologic Inc (HOLX)

$67.16 +0.34 (0.51%)
Market Cap 14.89B
Revenue (ttm) 4.03B
Net Income (ttm) 789.50M
EPS (ttm) N/A
PE Ratio 15.66
Forward PE 15.49
Profit Margin 19.59%
Debt to Equity Ratio 0.55
Volume 1,874,000
Avg Vol 2,812,080
Day's Range N/A - N/A
Shares Out 222.85M
Stochastic %K 90%
Beta 0.55
Analysts Sell
Price Target $70.73

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, an...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 508 263 2900
Address:
250 Campus Drive, Marlborough, United States
IN0V8
IN0V8 Aug. 1 at 6:29 PM
$HOLX Mizuho raises target price to $75 from $70 Morgan Stanley raises target price to $69.00 from $65.00
0 · Reply
Fiolek
Fiolek Aug. 1 at 9:29 AM
$HOLX
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 31 at 3:29 PM
$HOLX Morgan Stanley Maintains Equal-Weight on Hologic, Raises Price Target to $69
0 · Reply
JarvisFlow
JarvisFlow Jul. 31 at 3:29 PM
Morgan Stanley has updated their rating for Hologic ( $HOLX ) to Equal-Weight with a price target of 69.
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 1:09 PM
$HOLX beats earnings but shares slip 0.7% in after-hours trading! 📉 Adjusted EPS of $1.08 beat estimates by 2.86%, and revenues climbed 1.2% year over year. Yet, U.S. revenues fell 0.6%, gross and operating margins contracted, and challenges in China and Africa loom over Diagnostics. Full breakdown here 👉 https://www.zacks.com/stock/news/2643105/hologic-stock-falls-despite-q3-earnings-and-revenue-beat-margins-down?cid=sm-stocktwits-2-2643105-body-4932&ADID=SYND_STOCKTWITS_TWEET_2_2643105_BODY_4932
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 11:37 AM
$HOLX beats on both earnings and revenues… so why’s the stock dropping? Margins took a hit in Q3 — that’s what’s weighing on the reaction. Full breakdown here 👉 https://www.zacks.com/stock/news/2643105/hologic-stock-falls-despite-q3-earnings-and-revenue-beat-margins-down?cid=sm-stocktwits-2-2643105-teaser-4920&ADID=SYND_STOCKTWITS_TWEET_2_2643105_TEASER_4920
0 · Reply
DonCorleone77
DonCorleone77 Jul. 30 at 9:06 PM
$HOLX Hologic reports Q3 adjusted EPS $1.08, consensus $1.05 -- Reports Q3 revenue $1.023B, consensus $1.01B. -- Sees Q4 adjusted EPS $1.09-$1.12, consensus $1.07 -- Sees Q4 revenue $1.03B-$1.04B, consensus $1.03B. -- Raises FY25 EPS view to $4.23-$4.26 from $4.15-$4.25, consensus $4.18 -- Narrows FY25 revenue view to $4.081B-$4.091B from $4.05B-$4.1B, consensus $4.07B.
0 · Reply
healthcareguru
healthcareguru Jul. 30 at 8:34 PM
$HOLX JUNK qtr, low quality beat from non-core segment…going right back down.
0 · Reply
ZacksResearch
ZacksResearch Jul. 29 at 1:01 PM
$HOLX struggles in Breast Health — but is a turnaround on the horizon? 📉 Despite HOLX shares declining 20.4% over the past year and a bearish EPS trend, Hologic expects a Q4 rebound for its Breast Health unit. Plus, service revenues rose 12% YoY in the second quarter, offering some stability. See if HOLX's strategy can lift its Zacks Rank #4 (Sell) stock 👉 https://www.zacks.com/stock/news/2633047/hologic-focuses-on-breast-health-turnaround-this-year-can-it-deliver?cid=sm-stocktwits-2-2633047-body-4372&ADID=SYND_STOCKTWITS_TWEET_2_2633047_BODY_4372
0 · Reply
ZacksResearch
ZacksResearch Jul. 29 at 11:40 AM
$HOLX is betting big on a breast health rebound — but can it execute? Management is prioritizing a turnaround in its Breast Health business in 2025, aiming to revive one of its core segments. Full breakdown of the plan and potential here 👉 https://www.zacks.com/stock/news/2633047/hologic-focuses-on-breast-health-turnaround-this-year-can-it-deliver?cid=sm-stocktwits-2-2633047-teaser-4354&ADID=SYND_STOCKTWITS_TWEET_2_2633047_TEASER_4354
0 · Reply
Latest News on HOLX
Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript

Jul 30, 2025, 7:12 PM EDT - 3 days ago

Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript

Hologic raises annual profit forecast on diagnostic and surgical demand

Jul 30, 2025, 6:06 PM EDT - 3 days ago

Hologic raises annual profit forecast on diagnostic and surgical demand

Hologic Announces Financial Results for Third Quarter of Fiscal 2025

Jul 30, 2025, 4:01 PM EDT - 3 days ago

Hologic Announces Financial Results for Third Quarter of Fiscal 2025

Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy

Jul 22, 2025, 5:06 PM EDT - 11 days ago

Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

Jul 2, 2025, 4:05 PM EDT - 4 weeks ago

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation

Jun 2, 2025, 11:03 AM EDT - 2 months ago

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

May 27, 2025, 3:48 PM EDT - 2 months ago

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports

May 27, 2025, 1:05 PM EDT - 2 months ago

Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports

BX TPG

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

May 22, 2025, 5:05 PM EDT - 2 months ago

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

Hologic to Webcast Presentations at Upcoming Investor Conferences

May 13, 2025, 4:10 PM EDT - 2 months ago

Hologic to Webcast Presentations at Upcoming Investor Conferences

Hologic: Soft Performance, But Cheap Enough

May 6, 2025, 5:39 PM EDT - 3 months ago

Hologic: Soft Performance, But Cheap Enough

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript

May 1, 2025, 8:24 PM EDT - 3 months ago

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript

Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty

May 1, 2025, 6:58 PM EDT - 3 months ago

Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty

Hologic Announces Financial Results for Second Quarter of Fiscal 2025

May 1, 2025, 4:01 PM EDT - 3 months ago

Hologic Announces Financial Results for Second Quarter of Fiscal 2025

Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medical, Zimmer Aesthetics & More

Apr 25, 2025, 4:25 AM EDT - 3 months ago

Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medical, Zimmer Aesthetics & More

Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI

Apr 24, 2025, 8:10 AM EDT - 3 months ago

Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI

Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

Apr 22, 2025, 8:08 AM EDT - 3 months ago

Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

Wayde McMillan Elected to Hologic Board of Directors

Apr 4, 2025, 4:15 PM EDT - 4 months ago

Wayde McMillan Elected to Hologic Board of Directors

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

Apr 3, 2025, 4:30 PM EDT - 4 months ago

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference

Feb 25, 2025, 8:15 AM EST - 5 months ago

Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

Feb 20, 2025, 3:00 AM EST - 5 months ago

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Feb 18, 2025, 8:08 AM EST - 5 months ago

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 10:06 PM EST - 6 months ago

Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript

Hologic cuts annual revenue forecast on weak demand for breast health products

Feb 5, 2025, 5:56 PM EST - 6 months ago

Hologic cuts annual revenue forecast on weak demand for breast health products

Hologic Announces Financial Results for First Quarter of Fiscal 2025

Feb 5, 2025, 4:01 PM EST - 6 months ago

Hologic Announces Financial Results for First Quarter of Fiscal 2025

New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide

Jan 21, 2025, 8:00 AM EST - 6 months ago

New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide

Hologic: Reasonably, But Not Compellingly Valued

Jan 17, 2025, 1:28 PM EST - 7 months ago

Hologic: Reasonably, But Not Compellingly Valued

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

Jan 12, 2025, 4:00 PM EST - 7 months ago

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

Hologic to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:04 PM EST - 7 months ago

Hologic to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Hologic to Announce Financial Results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025

Jan 6, 2025, 4:15 PM EST - 7 months ago

Hologic to Announce Financial Results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025

Hologic Completes Acquisition of Gynesonics, Inc.

Jan 6, 2025, 8:05 AM EST - 7 months ago

Hologic Completes Acquisition of Gynesonics, Inc.

Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz

Jan 3, 2025, 12:06 PM EST - 7 months ago

Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz

ABT BMY LLY NVO UNH XBI XLV

Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC

Dec 18, 2024, 8:08 AM EST - 8 months ago

Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC

Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines

Dec 10, 2024, 4:01 PM EST - 8 months ago

Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines

Martin Madaus Elected to Hologic Board of Directors

Dec 9, 2024, 4:05 PM EST - 8 months ago

Martin Madaus Elected to Hologic Board of Directors

New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence

Dec 9, 2024, 8:05 AM EST - 8 months ago

New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence

Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations

Dec 2, 2024, 8:08 AM EST - 8 months ago

Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations

Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024

Nov 25, 2024, 8:22 AM EST - 8 months ago

Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024

Hologic, Inc. (HOLX) Q4 2024 Earnings Call Transcript

Nov 4, 2024, 7:26 PM EST - 9 months ago

Hologic, Inc. (HOLX) Q4 2024 Earnings Call Transcript

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024

Nov 4, 2024, 4:01 PM EST - 9 months ago

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024

Hologic to acquire Gynesonics in $350M deal to boost Fibroid treatments

Oct 19, 2024, 2:00 PM EDT - 10 months ago

Hologic to acquire Gynesonics in $350M deal to boost Fibroid treatments

Hologic Adds Gynesonics' Sonata System In $350M Acquisition To Boost Fibroid Treatments

Oct 14, 2024, 2:07 PM EDT - 10 months ago

Hologic Adds Gynesonics' Sonata System In $350M Acquisition To Boost Fibroid Treatments

Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women's Health

Oct 14, 2024, 8:05 AM EDT - 10 months ago

Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women's Health

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2024 on Monday, November 4, 2024

Oct 4, 2024, 8:22 AM EDT - 10 months ago

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2024 on Monday, November 4, 2024

Hologic CEO Steve MacMillan on breast cancer detection, future of AI-powered diagnostics

Oct 1, 2024, 9:12 AM EDT - 10 months ago

Hologic CEO Steve MacMillan on breast cancer detection, future of AI-powered diagnostics

Hologic Unveils #BustTheMyth Campaign to Debunk Breast Cancer Myths and Empower Women This Breast Cancer Awareness Month

Sep 30, 2024, 9:17 AM EDT - 10 months ago

Hologic Unveils #BustTheMyth Campaign to Debunk Breast Cancer Myths and Empower Women This Breast Cancer Awareness Month

Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 29, 2024, 8:08 AM EDT - 1 year ago

Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference

Hologic CEO on earnings beat: our Covid work has 'turbocharged' diagnostics business

Jul 30, 2024, 12:50 PM EDT - 1 year ago

Hologic CEO on earnings beat: our Covid work has 'turbocharged' diagnostics business

Hologic Analysts Boost Their Forecasts After Q3 Results

Jul 30, 2024, 9:05 AM EDT - 1 year ago

Hologic Analysts Boost Their Forecasts After Q3 Results

Hologic, Inc. (HOLX) Q3 2024 Earnings Call Transcript

Jul 29, 2024, 8:40 PM EDT - 1 year ago

Hologic, Inc. (HOLX) Q3 2024 Earnings Call Transcript

IN0V8
IN0V8 Aug. 1 at 6:29 PM
$HOLX Mizuho raises target price to $75 from $70 Morgan Stanley raises target price to $69.00 from $65.00
0 · Reply
Fiolek
Fiolek Aug. 1 at 9:29 AM
$HOLX
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 31 at 3:29 PM
$HOLX Morgan Stanley Maintains Equal-Weight on Hologic, Raises Price Target to $69
0 · Reply
JarvisFlow
JarvisFlow Jul. 31 at 3:29 PM
Morgan Stanley has updated their rating for Hologic ( $HOLX ) to Equal-Weight with a price target of 69.
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 1:09 PM
$HOLX beats earnings but shares slip 0.7% in after-hours trading! 📉 Adjusted EPS of $1.08 beat estimates by 2.86%, and revenues climbed 1.2% year over year. Yet, U.S. revenues fell 0.6%, gross and operating margins contracted, and challenges in China and Africa loom over Diagnostics. Full breakdown here 👉 https://www.zacks.com/stock/news/2643105/hologic-stock-falls-despite-q3-earnings-and-revenue-beat-margins-down?cid=sm-stocktwits-2-2643105-body-4932&ADID=SYND_STOCKTWITS_TWEET_2_2643105_BODY_4932
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 11:37 AM
$HOLX beats on both earnings and revenues… so why’s the stock dropping? Margins took a hit in Q3 — that’s what’s weighing on the reaction. Full breakdown here 👉 https://www.zacks.com/stock/news/2643105/hologic-stock-falls-despite-q3-earnings-and-revenue-beat-margins-down?cid=sm-stocktwits-2-2643105-teaser-4920&ADID=SYND_STOCKTWITS_TWEET_2_2643105_TEASER_4920
0 · Reply
DonCorleone77
DonCorleone77 Jul. 30 at 9:06 PM
$HOLX Hologic reports Q3 adjusted EPS $1.08, consensus $1.05 -- Reports Q3 revenue $1.023B, consensus $1.01B. -- Sees Q4 adjusted EPS $1.09-$1.12, consensus $1.07 -- Sees Q4 revenue $1.03B-$1.04B, consensus $1.03B. -- Raises FY25 EPS view to $4.23-$4.26 from $4.15-$4.25, consensus $4.18 -- Narrows FY25 revenue view to $4.081B-$4.091B from $4.05B-$4.1B, consensus $4.07B.
0 · Reply
healthcareguru
healthcareguru Jul. 30 at 8:34 PM
$HOLX JUNK qtr, low quality beat from non-core segment…going right back down.
0 · Reply
ZacksResearch
ZacksResearch Jul. 29 at 1:01 PM
$HOLX struggles in Breast Health — but is a turnaround on the horizon? 📉 Despite HOLX shares declining 20.4% over the past year and a bearish EPS trend, Hologic expects a Q4 rebound for its Breast Health unit. Plus, service revenues rose 12% YoY in the second quarter, offering some stability. See if HOLX's strategy can lift its Zacks Rank #4 (Sell) stock 👉 https://www.zacks.com/stock/news/2633047/hologic-focuses-on-breast-health-turnaround-this-year-can-it-deliver?cid=sm-stocktwits-2-2633047-body-4372&ADID=SYND_STOCKTWITS_TWEET_2_2633047_BODY_4372
0 · Reply
ZacksResearch
ZacksResearch Jul. 29 at 11:40 AM
$HOLX is betting big on a breast health rebound — but can it execute? Management is prioritizing a turnaround in its Breast Health business in 2025, aiming to revive one of its core segments. Full breakdown of the plan and potential here 👉 https://www.zacks.com/stock/news/2633047/hologic-focuses-on-breast-health-turnaround-this-year-can-it-deliver?cid=sm-stocktwits-2-2633047-teaser-4354&ADID=SYND_STOCKTWITS_TWEET_2_2633047_TEASER_4354
0 · Reply
John_Wick1234
John_Wick1234 Jul. 28 at 11:11 AM
$HOLX Price Cross above 200 EMA.
0 · Reply
ZacksResearch
ZacksResearch Jul. 25 at 2:13 PM
$EXAS vs. $HOLX — Why Exact Sciences might be the smarter choice right now! 🔍 📈 Exact Sciences is riding high on Cologuard adoption with a bullish Zacks Rank #2 (Buy) and EPS estimates showing a 169.6% improvement for 2025. 📉 Meanwhile, Hologic's facing tariff pressures, softer demand, and a Zacks Rank #4 (Sell). Find out why EXAS could outperform HOLX 👉 https://www.zacks.com/stock/news/2616843/holx-vs-exas-which-cancer-diagnostics-stock-should-you-retain-now?cid=sm-stocktwits-2-2616843-body-3886&ADID=SYND_STOCKTWITS_TWEET_2_2616843_BODY_3886
0 · Reply
ZacksResearch
ZacksResearch Jul. 25 at 1:09 PM
$EXAS pulling ahead of $HOLX — here’s why it matters 🧬 Rising Cologuard adoption, new product launches, and bullish EPS trends are giving EXAS the upper hand in cancer diagnostics. See the full retention case here 👉 https://www.zacks.com/stock/news/2616843/holx-vs-exas-which-cancer-diagnostics-stock-should-you-retain-now?cid=sm-stocktwits-2-2616843-teaser-3843&ADID=SYND_STOCKTWITS_TWEET_2_2616843_TEASER_3843
0 · Reply
Powell6531
Powell6531 Jul. 24 at 2:15 PM
$HOLX
0 · Reply
ZacksResearch
ZacksResearch Jul. 24 at 2:14 PM
$HOLX is down 8.5% YTD — is it undervalued or a value trap? 🤔 🚀 International Surgical business up 16.2% in fiscal Q2 2025, but global challenges persist 📉 Trading at a forward P/E of 14.84X, below industry average of 28.28X ⚠️ Zacks Rank #4 (Sell) with downward EPS estimate trend Is it worth the risk? Full analysis here 👉 https://www.zacks.com/stock/news/2612097/hologics-international-momentum-takes-shape-will-execution-pay-off?cid=sm-stocktwits-2-2612097-body-3536&ADID=SYND_STOCKTWITS_TWEET_2_2612097_BODY_3536
0 · Reply
ZacksResearch
ZacksResearch Jul. 24 at 12:08 PM
International tailwind building for $HOLX — is it finally ready to break out? Surgical division strength + untapped global demand are fueling a real push overseas, and HOLX looks like it’s leaning in hard. Find out if this execution can deliver upside 👉 https://www.zacks.com/stock/news/2612097/hologics-international-momentum-takes-shape-will-execution-pay-off?cid=sm-stocktwits-2-2612097-teaser-3479&ADID=SYND_STOCKTWITS_TWEET_2_2612097_TEASER_3479
0 · Reply
ZacksResearch
ZacksResearch Jul. 22 at 1:36 PM
$HOLX faces a rocky road ahead — is it time to sell? 🚩 With a Zacks Rank #4 (Sell) and no Earnings ESP advantage, Hologic's Q3 projections show a decline in top and bottom-line performance, compounded by macroeconomic and industry pressures. Understand the risks before investing in HOLX 👉 https://www.zacks.com/stock/news/2602852/is-hologic-stock-a-risky-investment-ahead-of-its-q3-earnings-report?cid=sm-stocktwits-2-2602852-body-2964&ADID=SYND_STOCKTWITS_TWEET_2_2602852_BODY_2964
0 · Reply
ZacksResearch
ZacksResearch Jul. 22 at 11:52 AM
Tariffs rising, estimates falling — is $HOLX a trap before earnings? Q3 revenue and EPS estimates are trending lower, tariffs are pressuring margins, and the stock is underperforming its peers. Full risk breakdown before the print 👉 https://www.zacks.com/stock/news/2602852/is-hologic-stock-a-risky-investment-ahead-of-its-q3-earnings-report?cid=sm-stocktwits-2-2602852-teaser-2957&ADID=SYND_STOCKTWITS_TWEET_2_2602852_TEASER_2957
0 · Reply
IN0V8
IN0V8 Jul. 18 at 5:18 PM
$HOLX Opportunity BofA Global Research raises price objective to $70 from $64
0 · Reply
ZacksResearch
ZacksResearch Jul. 16 at 1:07 PM
$HOLX: Is the AI Edge Enough to Counter Stock Slide? 🤔 Hologic's Genius AI Detection 2.0 shows consistent results across diverse populations, but the stock is down 12.3% YTD compared to the industry’s 10.2% fall and carries a Zacks Rank #4 (Sell). 📉 Understand the risks before investing in HOLX 👉 https://www.zacks.com/stock/news/2585106/hologic-rides-on-ai-powered-breast-health-innovations-whats-next?cid=sm-stocktwits-2-2585106-body-1989&ADID=SYND_STOCKTWITS_TWEET_2_2585106_BODY_1989
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 12:31 PM
Mizuho has updated their rating for Hologic ( $HOLX ) to Outperform with a price target of 70.
0 · Reply
ZacksResearch
ZacksResearch Jul. 16 at 11:57 AM
$HOLX rides the AI wave in breast health — is this just the beginning? With tools like Genius Detection PRO and the soon-to-launch Envision 3D platform, HOLX is doubling down on innovation in a critical care segment. Find out what’s driving momentum and what’s next 👉 https://www.zacks.com/stock/news/2585106/hologic-rides-on-ai-powered-breast-health-innovations-whats-next?cid=sm-stocktwits-2-2585106-teaser-1956&ADID=SYND_STOCKTWITS_TWEET_2_2585106_TEASER_1956
0 · Reply